Prot #INCB 59872-101: A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies

Project: Research project

Project Details

StatusFinished
Effective start/end date4/14/16 → 4/14/22

Funding

  • inVentiv Health Clinical (Prot #INCB 59872-101 // Prot #INCB 59872-101)
  • Incyte Corporation (Prot #INCB 59872-101 // Prot #INCB 59872-101)